Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Conferences | Events

Re-Pharm to Present at IDDST, Nanjing, China and Available for One-to-One Meetings, 16-19 November 2016

publication date: Nov 16, 2016
 | 
author/source: Re-Pharm

Re-Pharm, an early-stage drug discovery and development company that uses computational chemistry for re-profiling, is pleased to announce that Dr Robert Scoffin, CEO, will be presenting at the Annual Congress of International Drug Discovery Science and Technology (IDDST) in Nanjing, China on 16-19 November 2016.

re-pharmDr Scoffin will also be available for one-to-one partnering meetings throughout the show. Dr Scoffin’s talk, ‘Finding new uses for an old drug through computational chemistry – re-profiling of RP0217 as a novel topical anti-inflammatory treatment’, on Saturday 19th November, will describe Re-Pharm’s smart re-profiling platform, which has been used to discover novel anti-inflammatory activity for a 60 year old drug.

Re-Pharm is actively looking for partners to progress the anti-inflammatory compound RP0217 through early clinical development and clinical trials. Re-Pharm holds patents on the use of RP0217 for the treatment or prevention of respiratory and gastrointestinal inflammatory disorders and for its use with and without co-formulated or co-administered steroids in topical ophthalmic indications, specifically conjunctivitis and uveitis, and prophylactic use in surgical applications such as LASIK.

“Re-Pharm uses in silico approaches to rapidly explore re-profiling and re-purposing opportunities for marketed compounds,” explains Scoffin. “Compounds with potential are progressed rapidly through our optimization and validation process. Re-purposed compounds such as RP0217 have significant bodies of safety data available, which typically result in shortened routes to regulatory approval.”


more about re-pharm


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

Today's Picks

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.